Background: Acquired immunodeficiency associated with thymoma is a rare disorder. Here we reported a case of acquired immunodeficiency with thymoma, with an unusual pattern of low CD4 + count with normal gammaglobulin levels. Case presentation: A 70-year-old man presented to the emergency room of our hospital with a high-grade fever, headache, and nausea. He had a five-year history of unresectable thymoma treatment, including several cytotoxic regimens. He had received thoracic palliative radiotherapy 2 months prior to the emergent visit. During the previous month, he had experienced multiple febrile episodes, dry cough, fatigue, weight loss, and watery diarrhea. Upon admission, he had a high-grade fever, nausea, and immobility. Physical examination revealed indistinct consciousness, neck stiffness, and oropharyngeal candidiasis. Both cerebrospinal fluid and blood cultures yielded multiple short chains of Gram-positive rods later identified as Listeria monocytogenes, so he was diagnosed with Listeria meningitis. Intravenous administration of antibiotics was initiated, and the patient fully recovered and was discharged. Additional examination found normal immunoglobulin levels. Peripheral-blood cell counts revealed low CD4 + cell count (108 CD4 + cells/μl). His CD4 + cell count remained low after discharge.
Background
Acquired immunodeficiency associated with thymoma, represented by Good syndrome, is a rare disorder. Good syndrome was first described more than 60 years ago, characterized by humoral immunodeficiency of hypogammaglobulinemia often with the onset after thymectomy [1] . Here we report a case of acquired cellular immunodeficiency that was induced immediately after radiotherapy for thymoma, with an atypical pattern of low CD4 + count with normal gammaglobulin levels.
Case presentation
A 70-year-old man presented to the emergency room of Shizuoka Cancer Center with a high-grade fever, headache, and nausea. He had a five-year history of unresectable thymoma (Masaoka stage IVa; Fig. 1 ) treatment, including cisplatin and amrubicin, amrubicin monotherapy, and a phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor which was discontinued due to tumor progression 12 months prior. Two months prior, he had received thoracic radiotherapy (40 Gy with 20 fractions) for palliation of chest pains due to multiple pleural disseminated lesions. During the previous month, he had experienced multiple febrile episodes, dry cough, fatigue, weight loss, and watery diarrhea. Upon admission, he had a fever (≥40°C), nausea, and immobility. Physical examination revealed indistinct consciousness, neck stiffness, and oropharyngeal candidiasis. The patient's white blood cell count was 15, 380 cells/μl with 91% granulocytes, and biochemical examination revealed elevated AST/ALT levels (81 and 153 IU/L, respectively). Both cerebrospinal fluid and blood cultures yielded multiple short chains of Gram-positive rods later identified as Listeria monocytogenes, so he was diagnosed with Listeria meningitis (Fig. 2) . Intravenous administration of vancomycin (1 g/12 h) and ceftriaxone (2 g/12 h) was initiated, followed by ampicillin (2 g/4 h) and gentamicin (80 mg/8 h) for three weeks. The patient fully recovered and was discharged.
Additional examination found normal levels of total IgG (1148 mg/dL), IgM (57 mg/dL), and IgA (156 mg/dL). Flowcytometric analysis of peripheral-blood cells disclosed 528 lymphocytes/μl (normal range, 1000-3100 lymphocytes/μl), 
Discussion and conclusions
To our knowledge, few reports have discussed immunodeficiency identified after radiotherapy for thymoma. Patients with immunodeficiency often exhibit respiratory tract infections and chronic diarrhea [2] [3] [4] . Thus, the patient's frequent diarrhea might have been an early manifestation. Furthermore, he had oral candidiasis and Listeria meningitis, which may reflect a dysfunction in T-cell mediated immunity [5] .
As originally described, Good Syndrome is hypogammaglobinemia in patients with underlying thymoma. However, our peripheral blood examination revealed a rarely reported pattern of low CD4 + count with normal gammaglobulin levels, more typical of HIV infection [6] .
The proportion of peripheral CD45RA + T cells reportedly decreases after thymoma resection [7] . Additionally, adults have deficiencies in thymus-dependent CD4 + T lymphocyte regeneration; therefore, rapid T-cell regeneration requires residual thymic function in patients receiving high-dose chemotherapy [8] . One possible explanation is the large volume reduction caused by radiotherapy also induces similar systemic immune response, leading to acquired immunodeficiency [9] . However, a direct relationship between radiotherapy and immunodeficiency was not proven because the CD4+ cell count before radiotherapy was not measured in this case. A previous report suggested that cellular immunodeficiency associated with thymoma was not uncommon, but is frequently overlooked [10] . In this case, it was possible that the patient already had undiagnosed cellular immunodeficiency before radiotherapy. In thymoma cases, CD4 levels may have to be measured frequently over time, irrelevant of whether the baseline immunoglobulin levels are within the range or not. Correct diagnosis would provide treatment of the paraneoplastic Good syndrome to avoid complications induced by therapies such as radiotherapy, chemotherapy, and surgery.
In conclusion, we reported a case of acquired cellular immunodeficiency in a patient with thymoma. Our findings suggest that physicians need to be aware of severe infections due to immunodeficiency in patients with thymoma.
Abbreviations Gy: Gray; HIV: Human immunodeficiency virus; IU: International unit in the diagnosis and management of the patient, and revised the manuscript for important intellectual content. ME participated in the diagnosis of the patient by conducting the radiographic investigations. TT takes responsibility for (is the guarantor of) the content of the case report. H. Kobayashi, KN, SO, KW, AO, H. Kenmotsu, and HM helped writing and reviewed the manuscript.
Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Availability of data and materials
All data in this report is confidential patient information which is kept as part of the medical record at the site of care.
Ethics approval and consent to participate Not applicable as this is not an interventional study. The need for approval was waived by the Shizuoka Cancer Center Institutional Review Board.
Consent for publication
Written consent for publication was obtained from the patient described and is available for review.
Competing interests H.K. has received honoraria from Eli Lilly Japan K.K. and Taiho Pharmaceutical Co. Ltd. K.N. has received honoraria from Chugai Pharmaceutical Co. Ltd., Novartis Pharma K.K., and Taiho Pharmaceutical Co. Ltd. S.O. has received honoraria from Chugai Pharmaceutical Co. Ltd., Ono Pharmaceutical Co. Ltd., AstraZeneca K.K., Boehringer Ingelheim Japan Inc., Taiho Pharmaceutical Co. Ltd., and MSD K.K. K.W. has received honoraria from Eli Lilly Japan K.K., Chugai Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., Boehringer Ingelheim Japan Inc., Ono Pharmaceutical Co. Ltd., and MSD K.K. A.O. has received honoraria from Chugai Pharmaceutical Co. Ltd., Novartis Pharma K.K., Ono Pharmaceutical Co. Ltd., Bristol-Myers Squibb Co. Ltd., and Taiho Pharmaceutical Co. Ltd.; and research funding from Chugai Pharmaceutical Co. Ltd. and Taiho Pharmaceutical Co. Ltd. H.K. has received honoraria from Eli Lilly Japan K.K., Chugai Pharmaceutical Co. Ltd., AstraZeneca K.K., Ono Pharmaceutical Co. Ltd., Boehringer Ingelheim Japan Inc., Novartis Pharma K.K., Bristol-Myers Squibb Co. Ltd., Kyowa Hakko Kirin Co. Ltd., and MSD K.K.; and research funding from AstraZeneca K.K., Chugai Pharmaceutical Co. Ltd. and Boehringer Ingelheim Japan Inc. H.M. has received honoraria from AstraZeneca K.K., Eli Lilly Japan K.K., Chugai Pharmaceutical Co. Ltd., Boehringer Ingelheim Japan Inc., Pfizer Inc., Taiho Pharmaceutical Co. Ltd., Novartis Pharma K.K., Bristol-Myers Squibb Co. Ltd., and Ono Pharmaceutical Co. Ltd. T.T. has received grants and honoraria from Ono Pharmaceutical Co. Ltd., MSD K.K., AstraZeneca K.K., Eli Lilly Japan K.K., Chugai Pharmaceutical Co. Ltd.; grants from Pfizer Inc.; and honoraria from Boehringer Ingelheim Japan Inc., and Roche Diagnostics K.K. The remaining author declares no conflict of interest. 
Author details

